Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen and Abnegix reveal new tumour growth retardant

Amgen and Abnegix reveal new tumour growth retardant

4th November 2005

Amgen and Abnegix have announced that their experimental drug panitumumab has been shown in a late stage study to help slow tumour growth in patients with advanced stage colon cancer who had failed to respond to chemotherapy.

In the trials on 463 patients, those who received panitumumab every two weeks showed a 46 per cent fall in the progression of tumours, against a control group who received the best supportive care alone, the companies said. The result was up on the 33 per cent fall in tumour progression initially predicted in the trials, they added.

Panitumumab is a monoclonal antibody which works by blocking a protein called epidermal growth that helps tumours grow. The drug has the potential to reach sales of over $1 billion annually, Merrill Lynch analyst Eric Ende said in a report.

“It is my belief that the best use of panitumumab will be much earlier in the course of this disease, where by retarding progress of the disease it could provide additional years of survival,” Roger Perlmutter, executive vice president of research and development at Amgen, told Reuters.

“In general the safety profile looks quite good for this therapy,” he added.

While full trial results have yet to be carried out, panitumumab may be more effective than Imclone’s Erbitux with fewer side effects and a more convenient dosing schedule which would enable it to dominate the colorectal cancer market, added Mr Ende.

Abgenix shares rose by 38.2 per cent, or $3.58, to $12.95 following the news, while shares of Amgen rose 4.4 per cent, or $3.25, to $77.15.

track© Adfero Ltd

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.